Skip to content

JBIO JBIO Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$106K
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.86M-20.0%
Annexon logo
AnnexonANNX
$632K-65.8%
Janux Therapeutics logo
Janux TherapeuticsJANX
$2.62M-37.8%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$2.06M-22.1%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$136K-85.8%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's accretion (amortization) of discounts and premiums, investments?
JBIO (JBIO) reported accretion (amortization) of discounts and premiums, investments of $493K in Q1 2026.
What does accretion (amortization) of discounts and premiums, investments mean?
This metric accounts for the non-cash adjustment to the carrying value of investment securities, reflecting the gradual recognition of interest income or expense over time. It represents the difference between the purchase price and the face value of debt securities held in the company's treasury. It is used to reconcile net income with actual cash flows generated from investment holdings.